Search
for
Sort by
Research 30 of 1000+
- Skin toxicity caused by EGFR antagonists—An autoinflammatory condition triggered by deregulated IL‐1 signaling?
- Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
- The TRPM5 Antagonist Triphenylphosphine Oxide Increases Sebaceous Lipogenesis and Modulates Immune Phenotype of Human Sebocytes in a TRPM5‐Independent Manner
- Data from Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
- Data from Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
- Skin toxicity of anti‐cancer therapy
- Pathogenesis and management of TRPV3-related Olmsted syndrome
- Suppression of Wnt/β-catenin signaling by EGF receptor is required for hair follicle development
- Erlotinib-Induced Skin Inflammation Is IL-1 Mediated in KC-Tie2 Mice and Human Skin Organ Culture
- Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib
- Drug Repurposing Patent Applications April–June 2021
- Hydroxychloroquine modulates the progression of experimentally induced benign prostatic hyperplasia in rats via targeting EGFR/ERK/STAT3 and AR/FOXO1/TRAIL pathways: computational and in vivo studies
- Cutaneous Adverse Effects of EGFR Therapy in Breast Cancer Treatment
- IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes
- EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor
- Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
- Cutaneous Drug Eruptions Associated with the Use of Biologies and Cutaneous Drug Eruptions Mimicking Specific Skin Diseases
- Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers
- Sesamin alleviates androgenetic alopecia by targeting the AR MAPK Wnt axis
- Topical Application of Aprepitant Inhibits Erlotinib-induced Facial Dermatitis/Hair Loss
- Nociceptive and Nonnociceptive Roles of TRPV3 and Its “Druggability”
- EGFR signaling is required for regenerative proliferation in the cochlea: Conservation in birds and mammals
- KGF and EGF signalling block hair follicle induction and promote interfollicular epidermal fate in developing mouse skin
- Piperonylic Acid Promotes Hair Growth by Activation of EGFR and Wnt/β-Catenin Pathway
- The control of hair growth: An overview
- Cutaneous Lymphadenoma Is a Distinct Trichoblastoma-like Lymphoepithelial Tumor With Diffuse Androgen Receptor Immunoreactivity, Notch1 Ligand in Reed-Sternberg–like Cells, and Common EGFR Somatic Mutations
- Oral medications for central serous chorioretinopathy: a literature review